Molecular Formula | C30H26N6O3 |
Molar Mass | 518.57 |
Density | 1.34±0.1 g/cm3 (20 ºC 760 Torr) |
Boling Point | 743.4±60.0 °C(Predicted) |
pKa | 7.73±0.50(Predicted) |
Overview | edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one) it is a central nervous system drug developed by Mitsubishi Corporation, Japan. It was approved for marketing by Japanese Ministry of Health and Welfare in April 2001. Edaravone is a kind of antioxidant and free radical scavenging drugs, which is mainly used in the treatment of cerebral hemorrhage and cerebral infarction. It has a strong free radical scavenging function and can effectively protect the nerve, this has important clinical significance for the treatment of acute cerebral infarction. In addition, it can also be used for radiation brain edema, traumatic subarachnoid hemorrhage, primary nephrotic syndrome, vascular parkinsonism, congestive heart failure, spinal cord injury, viral myocarditis, acute paraquat poisoning, carbon monoxide poisoning, treatment of peripheral facial neuritis. Edaravone is mainly used in clinical use as an injection type. In the process of production, storage and use, due to the influence of high temperature sterilization and other factors, it may produce corresponding related substances, leading to the decline of drug quality. |